Edition:
United States

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

2.00USD
17 Aug 2018
Change (% chg)

$0.25 (+14.29%)
Prev Close
$1.75
Open
$1.75
Day's High
$2.15
Day's Low
$1.70
Volume
64,417
Avg. Vol
6,395
52-wk High
$2.95
52-wk Low
$1.20

Chart for

About

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)

Overall

Beta: --
Market Cap(Mil.): $48.77
Shares Outstanding(Mil.): 24.38
Dividend: --
Yield (%): --

Financials

  CHMA.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -1.13 -- --
ROI: -44.64 12.92 12.63
ROE: -45.25 14.94 14.82

BRIEF-Chiasma Announces FDA Agreement To Redefine Certain Secondary Endpoints In Phase 3 Clinical Trial

* CHIASMA ANNOUNCES FDA AGREEMENT TO REDEFINE CERTAIN SECONDARY ENDPOINTS IN CHIASMA OPTIMAL PHASE 3 CLINICAL TRIAL

May 14 2018

BRIEF-Chiasma Reports Q1 Loss Per Share $0.29

* CHIASMA - EXPECTS EXISTING CASH, INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH ANTICIPATED RELEASE OF DATA FROM CHIASMA OPTIMAL TRIAL BY 2019 END Source text for Eikon: Further company coverage:

May 10 2018

BRIEF-Chiasma Inc Files For Mixed Shelf Of Up To $100 Million ‍​

* CHIASMA INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING‍​ Source text: (https://bit.ly/2DLHB1V) Further company coverage:

Mar 22 2018

BRIEF-Chiasma Q4 Loss Per Share $0.25

* ‍EXPECTS TO HAVE A CASH AND INVESTMENT BALANCE OF AT LEAST $35 MILLION AT END OF 2018​ Source text for Eikon: Further company coverage:

Mar 20 2018

Earnings vs. Estimates